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Summary: Protein 1, which is identical to human Clara cell Μτ ΙΟ4 protein, is a homodimeric, low molecular mass
protein (Mr 14000) and an effective inhibitor of phospholipase A2 activity. We have expressed this protein in E. coli
and characterized its physiochemical and biological properties. Using a pET expression system, about 1.7 mg of
purified recombinant protein 1 was obtained from 250 ml of E. coli culture. The amino-terminal sequence of recom-
binant protein 1 up to the 20th residue was identical to that of native protein 1 except for an extra methionine at
the ammo-terminus. On reversed-phase HPLC, recombinant protein 1 eluted at the same retention time as native
protein 1. The dose-response curves of recombinant protein 1 and native protein 1 in an enzyme-linked immunosor-
bent assay for protein 1 were identical. Recombinant protein 1 inhibited both porcine pancreas and cobra venom
phospholipase A2 activities. These results indicated that recombinant protein 1 is structurally and biologically iden-
tical to native protein 1. We found that recombinant protein 1 also inhibits phosphatidylinositol-specific phospholi-
pase C activity.
Introduction
Human Protein 1, also called Urine Protein 1, is a pro-
tein with a relative molecular mass of 14 000 on sodium
dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE). It consists of two identical subunits of 70
amino acids joined in anti-parallel fashion by two disul-
phide bridges (1). We purified this protein from the urine
of patients with renal failure and found that it is identical
to human Clara cell Mr 104 protein (hCCIO) (1); it is an
effective inhibitor of phospholipase A2l) activity (2) and
has been immunohistochemically detected in human en-
dometrium (3) and bronchoalveolar epithelium (4). Pro-
tein 1 is also present in prostate epithelium (5) and semi-
nal vesicles (6), which accounts for the higher protein 1
levels in male urine (7, 8). Since the structure, biological
functions and tissue distribution of protein 1 are similar
to those of rabbit uteroglobin, protein 1 is considered to
be the human counterpart of rabbit uteroglobin (9). Be-
sides the inhibition of phospholipase A2 activity (10), a
variety of biological functions have been proposed for
rabbit uteroglobin, such as the inhibition of chemotaxis
and phagocytosis of neutrophils and monocytes (11),
suppression of the maternal immunological reactions
against the foetus (12) and masking of male gamete im-
]) Enzymes:
Phospholipase A?, EC 3.1.1.4
Phosphatidylinositol-specific phospholipase C, EC 3.1.4.10.
munogenicity (13). To understand the biological role of
this protein, a large amount of homogeneous material
is required.
In this study, we describe an efficient production of re-
combinant protein 1 using the pET expression system.
The expressed recombinant protein 1 retained its native
structural and biological properties, including inhibitory
activity towards phospholipase A2. Furthermore, our
study showed that recombinant protein 1 also inhibited
phosphatidylinositol-specific phospholipase C1) activity.
Materials and Methods
Plasmid construction
A cDNA coding mature protein 1 was amplified by the polymerase
chain reaction (PCR) from cloned protein 1 cDNA in Xgtll (14)
using the primers: S'-CTCCGCTCATATGGAGATCTGCCC-
GAGC-3' and S'-GCTTCGGATCCCTAATTACACAGTGAGC-S1.
Amplification with these primers generated a cDNA having NDe I
and Bam HI restriction sites at the 5' and 3' ends, respectively,
which facilitated cloning into the pET21a(+) expression vector
(Novagen, Madison, WI, USA). PCR was performed with Gene-
Amp PCR reagents (Perkin-Elmer Cetus, Nonvalk, CT, USA).
Thirty cycles were performed. Each consisted of denaturation at
94 °C for l min, annealing at 68 °C for l min and elongation at
72 °C. Amplified mature protein 1 cDNA and the vector
pET21a(+) were digested with Nde\ and Bam HI, ligated and
transformed into E. coli strain BL2l(DE3)pLysS competent cells
(Novagen) according to the supplier's protocol. The presence of a
protein 1 insert in recombinant clones was confirmed by PCR. Di-
rect sequencing was performed using a DNA sequencing kit (Bio-
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tinylated terminator Sequencing high -Plus-, Toyobo, Osaka, Ja-
pan).
Expression in E. coli
Clones were grown for 3 hours at 37 °C in 5 ml of Luria-Bertani
medium containing 50 mg/1 of ampicillin (resistance conferred by
pET21a(+)) and 34 mg/1 of chloramphenicol (resistance conferred
by pLys). Cells were then collected by centrifugation (3000 g,
5 min, 4 °C), resuspended in 250 ml of fresh Luria-Bertani medium
containing the same dose of antibiotics and cultured at 37 °C to an
absorbance at 650 nm of 1.2. Protein synthesis was initiated by
adding 1 mmol/1 isopropyl- -D-thiogalactopyranoside. After 30
min, 200 mg/1 rifampicin were added to inhibit E. coli RNA poly-
merase. The incubation was continued for 90 min to allow the
preferential expression of protein 1 via the rifampicin-resistant T7
RNA polymerase which is produced by BL21(DE3)pLysS E. coli
in the presence of isopropyl- -D-thiogalactopyranoside.
Pur i f ica t ion of recombinant protein 1
Cells expressing recombinant protein 1 were collected by centrifu-
gation (3000, 10 min, 4 °C) and stored at -20 °C until use.
Thawed cells were resuspended in 50 ml of 30 mmol/1 Tris-HCl
(pH 8.0) containing 30 mmol/1 NaCl, sonicated for 5 min on ice
at 50 W using an ultrasonic disruptor (Tomy, Tokyo, Japan) and
centrifuged (20000g, 30 min, 4 °C). The supernatant was applied
to an anti-protein 1 monoclonal antibody-conjugated Sepharose 4B
(Pharmacia, Uppsala, Sweden) column (2.5 cm X 15 cm I.D.).
Bound fractions rich in recombinant protein 1 were eluted with 0.2
mol/1 glycine-HCl (pH 2.5), then purified by high performance li-
quid chromatography (HPLC) using a reversed-phase column
^Bondasphere 5 um C4-300A, 150 mm X 3.9 mm I.D., Waters,
Milford, MA, USA). Immunoaffmity chromatography and HPLC
were performed as described (1). Amino-terminal sequences of
purified recombinant protein 1 were determined with a gas-phase
amino acid sequencer model PPSQ-10 (Shimazu, Kyoto, Japan)
according to the manufacturer's instructions.
Enzyme-l inked immunosorbent assay for protein 1
The immunochemical behaviour of recombinant protein 1 was in-
vestigated by means of a sandwich-type enzyme-linked immuno-
sorbent assay (ELISA) using an anti-protein 1 monoclonal antibody
(1) and a rabbit anti-protein 1 polyclonal antibody (DAKO, Copen-
hagen, Denmark) as described (1, 15).
Sodium dodecyl sulphate-polyacrylamide gel
electrophoresis and immunoblot t ing analysis
SDS-PAGE was performed according to Schagger & von Jagow
(16). Proteins separated by SDS-PAGE were electrotransferred
onto a polyvinylidene difluoride membrane (Millipore, Bedford,
MA, USA), then stained using the anti-protein 1 monoclonal anti-
body as described (1).
Assay of phospholipase A2 act ivi ty
To examine the effect of recombinant protein 1 on phospholipase
A2 activity, phospholipase A2 was preincubated at 37 °C for 5 min
with serial dilutions of recombinant protein 1 or vehicle. Phospho-
lipase A2 activity was then analysed according to Natori et al. (17)
with a slight modification. Briefly, the assay mixture (100 μΐ) con-
tained 100 mmol/1 Tris-HCl (pH 9.0), 4 mmol/1 CaCl2, 1.1 g/1 fatty
acid-free bovine serum albumin, 2 μτηοΐ/ΐ 1-stearoyl, 2-[l-I4C]ar-
achidonyl phopshatidylcholine (1.85-2.2 GBq/mmol, Amersham,
Buckinghamshire, UK), 0-2 μηιοΐ/ΐ recombinant protein 1 and 200
μπιοΐ/ΐ porcine pancreas phospholipase A2 (Boehringer Mannheim,
Indianapolis, IN, USA) or 100 pmol/1 cobra (Naja naja) venom
phopsholipase A2 (Sigma, St. Louis, MO, USA). The reaction was
started by adding aliquots of the enzyme-recombinant protein 1
mixture to the radioactive substrate. After a 20 min incubation at
37 °C, the reaction was stopped by adding 500 μΐ of Dole's reagent
(18) and heating to 60 °C for 2 min. The free fatty acid released
into the organic solvent was extracted by adding of 200 μΐ of H2O
and 300 μΐ of /i-heptanc. After vortex mixing, the radioactivity in
the /i-heptane phase was measured in a liquid-scintillation counter
and the inhibition rate of phospholipase A2 activity was calculated.
Assay of phosphol ipase C act ivi ty
Recombinanl phosphatidylinositol-specific phospholipase C-51
was purified to homogeneity as described (19). Phosphatidylinosi-
tol 4,5-bisphosphate phospholipase C activity of the enzyme in the
presence or absence of 2 μιηοΐ/ΐ recombinant protein 1 was mea-
sured according to Smrcka et al. (20). Briefly, the assay mixture
(50 μΐ) contained 0.25 pmol/1 of purified recombinant phosphati-
dylinositol-specific phospholipase C-51, various concentrations
(12.5-200 μηιοΐ/ΐ) of phosphatidylinositolA5-bisphosphate con-
taining 3H-labeIled isotype (370 GBq/mmol, NEN Dupont, Wil-
mington, DE, USA), phosphatidylethanolamine (Sigma) at a 10-
fold higher concentration than that of phosphatidylinositol 4,5-bis-
phosphate, 20 mmol/1 Hepes-NaOH (pH 7.2), 0.8 g/1 sodium chol-
ate, 1 mmol/1 dithiothreitol, 2 mmol/1 EGTA, 0.2 mmol/1 EDTA,
30 mmol/I KC1, 2 mmol/1 CaCl2 and 2 μηιοΐ/ΐ recombinant protein
1 or vehicle. The mixture was incubated for 2 min at 37 °C, then
the reaction terminated by transfer to 0 °C. Water-soluble hydroly-
sis products were extracted into 1 ml of chloroform/methanol/HCl
(100 + 100 + 0.6) and 0.3 ml of 1 mol/1 HC1 containing 5 mmol/1
EGTA. After vortex mixing the sample, the radioactivity of the
water phase was measured in a liquid-scintillation counter and the
initial rates of hydrolysis were calculated.
Results and Discussion
Expression and purification of recombinant
protein 1 in E. coli
Direct DNA sequencing of the protein 1 insert from the
selected clones verified that none of them was contami-
nated with PCR-induced sequence errors. Recombinant
protein 1 expression reached a maximum 2 hours after
induction by isopropyl- -jD-thiogalactopyranoside. The





Fig. 1 SDS-PAGE of fractions at each purification step. Samples
were resolved by electrophoresis under non-reducing conditions.
Lane 1, molecular mass markers;
lane 2, soluble fraction of E. coli lysates;
lane 3, insoluble fraction of E. coli lysates;
lane 4, pass-through fraction from anti-protein 1 immunoaffinity
gel;
lane 5, bound fraction to anti-protein 1 immunouffmity gel;
lane 6, purified recombinant protein 1.











Fig. 2 Chromatogram of reversed-phase HPLC. The position of
the recombinant protein 1-rich fraction is indicated by an arrow.
Insert: SDS-PAGE of purified protein 1. Purified recombinant pro-
tein 1 (lanes 1 and 2) and molecular mass markers (lane 3) were
resolved by electrophoresis either under non-reducing (lane 1) or
reducing (lanes 2 and 3) conditions.
the expression efficiency. About 3 mg of recombinant
protein 1 were expressed in 250 ml of culture. Immu-
noblotting showed that recombinant protein 1 was to-
tally dimeric in E. coll lysates (data not shown), suggest-
ing that synthesized recombinant protein 1 subunits were
immediately dimerized with interchain disulphide brid-
ges in E. coli.
Most recombinant protein 1 was recovered in the soluble
fractions of E. coli lysates, which simplified the purifi-
cation procedure. The anti-protein 1 immunoaffmity
chromatography alone removed most of contaminating
proteins derived from E. coli as judged by SDS-PAGE
(fig. 1, lane 5). Recombinat protein 1 was further puri-
fied to homogeneity by reversed-phase HPLC (fig. 2).
Finally, about 1.7 mg of purified recombinant protein 1
were obtained from 250 ml of E. coli culture. According
to our published findings (1), over 10 1 of pathological
urine were necessary to obtain an equivalent quantity.
Recombinant protein 1 was efficiently purified without




SDS-PAGE analysis showed that recombinant protein 1
was purified to homogeneity with a relative molecular
mass of 14 000 and 7000 under non-reducing and reduc-
ing conditions, respectively (fig. 2, insert). Recombinant
protein 1 also reacted with an anti-protein 1 monoclonal
antibody on immunoblotting (data not shown). On re-
versed-phase HPLC, recombinant protein 1 eluted at the
same retention time (42 min) as native protein 1 (fig. 2
and I.e. (1)). This indicated that the hydrophobicity of
recombinant protein 1, which is affected by the tertiary
structure of the protein, is very similar to that of native
protein 1. The ammo-terminal sequence of purified re-
combinant protein 1 was read up to the 20th residue and
proved identical to that of native protein 1 except for an
additional methionine at the amino-terminus of recombi-
nant protein 1. On ELISA for protein 1, serial dilutions
of recombinant protein 1 fitted the dose-response curve
of native protein 1 within the actual measurement range,
indicating that there was no difference in immunochemi-
cal behaviour between the two (fig. 3). All of the above
findings indicated that recombinant protein 1 and native
protein 1 are structurally identical, save for the presence
of an extra methionine at the amino-termunus of recom-
binant protein 1.
Effect on phospholipase A2 and
phospholipase C
Recombinant protein 1 inhibited both porcine pancreas
and cobra venom phospholipase A2 activity in a dose-
dependent manner (fig. 4), indicating that this recombi-
nant protein retained its important biological activities.
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Fig. 3 Dose-response curves of recombinant protein 1 (squares)
and native protein I (circles) on ELISA.
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Fig. 4 Dose-dependent inhibition of porcine pancreas (squares)
and cobra venom (circles) phospholipase A2 by recombinant pro-
tein 1.
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Fig. 5 Dose-dependent inhibition of recombinant phosphatidyli-
nositol-specifk phospholipase C-δΙ by recombinant protein 1.
phosphatidylcholine but also to phosphatidylinositol
(21). Therefore, we examined whether recombinant pro-
tein 1 inhibited phosphatidylinositol-specific phospholi-
pase C activity. Our data revealed that recombinant pro-
tein 1 also inhibits recombinant phosphatidylinositol-
specific phospholipase C-δΙ in a dose-dependent man-
ner (fig. 5). In the presence of 50 μπιοΙ/1 phosphatidyli-
nositol 4,5-bisphosphate and 0.25 pmol/1 recombinant
phosphatidylinositol-specific phospholipase C-51,
2 μιηοΐ/ΐ of recombinant protein 1 inhibited recombinant
phosphatidylinositol-specific phospholipase C-δΙ by
68%. To characterize the inhibition mechanism, we con-
structed Lineweaver-Burk plots. In the presence of
2 μηιοΐ/l recombinant protein 1, the Km value apparently
increased whereas the Kmax value remained unchanged
(fig. 6), indicating that the inhibition by recombinant
protein 1 is competitive.
Two possible mechanisms are considered for the inhibi-
tory effects of recombinant protein 1 on both phospholi-
pases. One is hydrophobia interaction between protein 1
and phospholipid substrates. Recombinant protein 1 may
limit phospholipase A2 and C binding to the lipid sub-
strates. Indeed, Umland et al. have shown that phospha-
tidylcholine and phosphatidylinositol bind to the inside
of the large internal hydrophobic cavity of protein 1
(21). The other mechanism is the sequestration of
calcium ions by protein 1. Both phospholipase A2 and
recombinant phosphatidylinositol-specific phospholi-
pase C-δΙ require calcium ions for their enzymatic activ-
ities. Andersson et al. have suggested that protein 1 in-
hibits phospholipase A2 activity by binding to calcium
ions (22). However, a search for protein sequence motifs
using the PROSITE (Univ. of Geneva) (23) and MOTIF
(Univ. of Kyoto) data libraries revealed that there was
no apparent calcium-binding domain such as an EF-
hand motif (24) in the amino-acid sequence of protein
1. Furthermore, our preliminary experiments employing
the 45Ca2+ equilibrium dialysis assay, the 45Ca2H" over-
lay assay or the Ca2+ gel shift assay (25) have so far
given no indication of recombinant protein 1 binding to
calcium ions (data not shown).
Inhibition of phospholipases may be the basis for the
biological functions of protein 1. As pointed out by other
workers, inhibition of phospholipase A2 may be impor-
tant in the regulation of inflammatory activity in the
lung. In particular the protein is likely to be instrumental
in controlling excess inflammatory activity (2, 9, 10).
Inhibition of the production and functional activity of
cytokines by protein 1 may add to its anti-inflammatory
activity (26). The protection against endogenous phos-
pholipases released by pulmonary cells is likely to be
500
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Fig. 6 Lineweaver-Burk plot of recombinant phosphatidylinosi-
tol-specific phospholipase C-51 activity with recombinant protein
l (squares) and without recombinant protein 1 (circles).
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important in chronic disorders, e. g. chronic obstructive
airway disease. Inhibition of bacterial phospholipases
would provide a defence against the deleterious effects
of microbial infections. In addition to down regulating
potential run-away inflammatory responses, the inhibi-
tion of phospholipase C and A2 is likely to preserve
the functional integrity of small airways be preventing
degradation of surfactant. Enhorning et al. have shown
that surfactant is important in maintaining the patency
of small airways (27, 28). They have also demon-
strated that degradation of surfactant by phospholi-
pases, in particular phospholipase C, impairs the bio-
logical activity of surfactant in the small airways.
Small airways generally bear the brunt of microbial
infections, e.g. bronchopneumonia, and the collapse
of such airways due to degradation of surfactant by
bacterial phospholipases can be expected to aggravate
the impairment of pulmonary function by pneumonia.
Inhibition of phospholipase C may be instrumental in
protecting the integrity of small airways by preserving
the biological activity of surfactant. Inhibition of phos-
pholipases may also be important in other chronic
lung disorders, e.g. asthma.
In conclusion, a large quantity of recombinant protein 1
was obtained, which retained its native structural and
biological properties. Using recombinant protein 1, we
found that protein 1 inhibited not only phospholipase
A2 but also phospholipase C activity. This recombinant
product will greatly facilitate biological and pharmaco-
logical studies on protein 1.
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